{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:39:50Z","timestamp":1792715990769,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ctrv.2026.103235","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:23:48Z","timestamp":1792481028000},"page":"103235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Role of maintaining the TKI backbone in oncogene-driven NSCLC after progression"],"prefix":"10.1016","volume":"151","author":[{"given":"Francesca","family":"Piazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Siniscalchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Moscvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Sangaletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Bestvina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Pietroluongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctrv.2026.103235_bb0005","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103235_bb0010","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","article-title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","volume":"40","author":"Saraon","year":"2021","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103235_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non\u2013small cell lung cancer, version 9.2026","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ctrv.2026.103235_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107438","article-title":"Drug resistance to targeted therapeutic strategies in non-small cell lung cancer","volume":"206","author":"Liu","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103235_bb0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer genomics portal: an open platform for exploring multidimensional Cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"7408","key":"10.1016\/j.ctrv.2026.103235_bb0030","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103235_bb0035","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-25-0960","article-title":"ELIOS: a multicenter, molecular profiling study of patients with EGFR-mutant advanced non\u2013small cell lung cancer treated with first-line osimertinib","volume":"16","author":"Piotrowska","year":"2026","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103235_bb0040","first-page":"330","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat Can"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103235_bb0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103235_bb0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -mutated advanced non\u2013small-cell lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103235_bb0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with Osimertinib plus chemotherapy in EGFR -mutated advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2026","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103235_bb0060","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in previously untreated EGFR -mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103235_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108747","article-title":"Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer","volume":"208","author":"Sun","year":"2025","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103235_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105807","article-title":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","volume":"10","author":"Peled","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103235_bb0075","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103235_bb0080","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1556-0864(25)00196-0","article-title":"1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD","volume":"20","author":"Le","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103235_bb0085","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.jtho.2025.06.002","article-title":"A pooled analysis of Datopotamab Deruxtecan in patients with EGFR-mutated NSCLC","volume":"20","author":"Ahn","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103235_bb0090","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103235_bb0095","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103235_bb0100","first-page":"962","article-title":"The selective c-met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-met activation in NSCLC models","volume":"7","author":"Friese-Hamim","year":"2017","journal-title":"Am J Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103235_bb0105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/1535-7163.MCT-22-0193","article-title":"Pharmacokinetic\/pharmacodynamic analysis of savolitinib plus osimertinib in an EGFR mutation\u2013positive, MET-amplified non\u2013small cell lung cancer model","volume":"22","author":"Jones","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"5827","key":"10.1016\/j.ctrv.2026.103235_bb0110","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung Cancer by activating ERBB3 Signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"17_suppl","key":"10.1016\/j.ctrv.2026.103235_bb0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8505","volume":"43","author":"Lu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103235_bb0120","doi-asserted-by":"crossref","first-page":"S978","DOI":"10.1016\/j.annonc.2021.08.1844","article-title":"1239P ORCHARD osimertinib + savolitinib interim analysis: a biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib","volume":"32","author":"Yu","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103235_bb0125","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103235_bb0130","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"De Marinis","year":"2025","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103235_bb0135","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1158\/1078-0432.CCR-23-2540","article-title":"Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven non\u2013small cell lung cancer with PIK3CA\/PTEN alterations","volume":"30","author":"Grazini","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103235_bb0140","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s11523-023-01005-0","article-title":"Intrinsic resistance to Osimertinib in EGFR mutated NSCLC cell lines induced by alteration in cell-cycle regulators","volume":"18","author":"Volta","year":"2023","journal-title":"Target Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103235_bb0145","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to Osimertinib in EGFR -mutant NSCLC and clinical validation of combined EGFR and RET inhibition with Osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103235_bb0150","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-22-2189","article-title":"Osimertinib and Selpercatinib efficacy, safety, and resistance in a Multicenter, prospectively treated cohort of EGFR -mutant and RET fusion-positive lung cancers","volume":"29","author":"Rotow","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103235_bb0155","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion\u2013positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103235_bb0160","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-14-2789","article-title":"EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors","volume":"21","author":"Ercan","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103235_bb0165","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.jtho.2019.07.016","article-title":"EGFR-mutated lung cancers resistant to Osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M\/C797S in preclinical models and clinical samples","volume":"14","author":"Rangachari","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103235_bb0170","article-title":"ORCHARD: osimertinib plus necitumumab in patients with epidermal growth factor receptor\u2013mutated advanced non\u2013small cell lung cancer with a secondary epidermal growth factor receptor alteration whose disease had progressed on first-line osimertinib","volume":"9","author":"Riess","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103235_bb0175","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103235_bb0180","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa2604461","article-title":"First-line Sunvozertinib in NSCLC with EGFR exon 20 insertion mutations","volume":"395","author":"Zhou","year":"2026","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103235_bb0185","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1200\/JCO-25-00763","article-title":"Zipalertinib in patients with epidermal growth factor receptor exon 20 insertion-positive non\u2013small cell lung cancer previously treated with platinum-based chemotherapy with or without amivantamab","volume":"43","author":"Piotrowska","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7153","key":"10.1016\/j.ctrv.2026.103235_bb0190","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103235_bb0195","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-07-6158","article-title":"Identification of novel isoforms of the EML4-ALK transforming gene in non\u2013small cell lung cancer","volume":"68","author":"Choi","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103235_bb0200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103235_bb0205","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line Lorlatinib or Crizotinib in advanced ALK -positive lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103235_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1285374","article-title":"Anaplastic lymphoma kinase inhibitors\u2014a review of anticancer properties, clinical efficacy, and resistance mechanisms","volume":"14","author":"Kie\u0142bowski","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103235_bb0215","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2147\/IJGM.S512395","article-title":"Mechanisms of resistance to ALK inhibitors and corresponding treatment strategies in lung cancer","volume":"18","author":"Xie","year":"2025","journal-title":"IJGM"},{"issue":"29","key":"10.1016\/j.ctrv.2026.103235_bb0220","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK -positive non\u2013small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103235_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108003","article-title":"Alectinib combined with cobimetinib in ALK-rearranged lung Cancer: a phase IB study","volume":"199","author":"Dagogo-Jack","year":"2025","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103235_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100342","article-title":"Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I\/II study","volume":"7","author":"Lin","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103235_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010204","article-title":"Phase II trial of the combination of Alectinib with bevacizumab in Alectinib refractory ALK-positive nonsquamous non-small-cell lung cancer (NLCTG1501)","volume":"15","author":"Watanabe","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103235_bb0240","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1038\/s41467-025-59744-9","article-title":"Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial","volume":"16","author":"Arrieta","year":"2025","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103235_bb0245","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173688","article-title":"MIG6 loss confers resistance to ALK\/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF","volume":"8","author":"Kondo","year":"2023","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103235_bb0250","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/1535-7163.MCT-23-0218","article-title":"MIG6 mediates adaptive and acquired resistance to ALK\/ROS1 fusion kinase inhibition through EGFR bypass Signaling","volume":"23","author":"Chen","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103235_bb0255","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/s12885-020-07057-z","article-title":"Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma","volume":"20","author":"Kang","year":"2020","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103235_bb0260","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"issue":"120","key":"10.1016\/j.ctrv.2026.103235_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired Crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103235_bb0270","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103235_bb0275","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013small-cell lung Cancer Harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"issue":"12_Supplement","key":"10.1016\/j.ctrv.2026.103235_bb0280","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-21-P05-01","article-title":"Abstract P05\u201301: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-mutated solid tumors","volume":"20","author":"Ramalingam","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"12_Supplement","key":"10.1016\/j.ctrv.2026.103235_bb0285","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-21-P05-02","article-title":"Abstract P05\u201302: A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)","volume":"20","author":"Gandara","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103235_bb0290","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-24-2310","article-title":"Impact of co-mutations and transcriptional signatures in non\u2013small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial","volume":"31","author":"Negrao","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103235_bb0295","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103235_bb0300","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung Cancer by combining Selpercatinib with Crizotinib","volume":"27","author":"Rosen","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103235_bb0305","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1158\/1078-0432.CCR-24-1762","article-title":"YAP regulates HER3 Signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancers","volume":"31","author":"Katayama","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103235_bb0310","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung Cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103235_bb0315","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","article-title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","volume":"25","author":"Wolf","year":"2024","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103235_bb0320","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung Cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103235_bb0325","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S2213-2600(24)00211-X","article-title":"Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study","volume":"12","author":"Yu","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103235_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101832","article-title":"SHP2 inhibition influences therapeutic response to Tepotinib in Tumors with MET alterations","volume":"23","author":"Pudelko","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.ctrv.2026.103235_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107442","article-title":"Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer","volume":"188","author":"Cho","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2026.103235_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103235_bb0345","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41591-025-04079-7","article-title":"Repotrectinib in NTRK fusion\u2013positive advanced solid tumors: a phase 1\/2 trial","volume":"32","author":"Besse","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103235_bb0350","doi-asserted-by":"crossref","first-page":"e2100418","DOI":"10.1200\/PO.21.00418","article-title":"Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion\u2013positive lung cancers","volume":"6","author":"Drilon","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103235_bb0355","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAPK pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103235_bb0360","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1535-7163.MCT-16-0909","article-title":"Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers","volume":"16","author":"Fuse","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103235_bb0365","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/cas.15263","article-title":"Utility of the Ba\/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer","volume":"113","author":"Koga","year":"2022","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103235_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114829","article-title":"ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models","volume":"43","author":"Schmid","year":"2024","journal-title":"Cell Rep"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103235_bb0375","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","article-title":"Sevabertinib in advanced HER2 -mutant non\u2013small-cell lung Cancer","volume":"393","author":"Le","year":"2025","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103235_bb0380","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2 -mutant non\u2013small-cell lung Cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N Engl J Med"},{"issue":"7_Supplement","key":"10.1016\/j.ctrv.2026.103235_bb0385","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1158\/1538-7445.AM2026-7025","article-title":"Abstract 7025: mechanisms of zongertinib resistance in HER2-mutant non-small cell lung cancer and potential strategies to overcome resistance","volume":"86","author":"Shibata","year":"2026","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103235_bb0390","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-21-3418","article-title":"The phase II MutHER study of neratinib alone and in combination with Fulvestrant in HER2-mutated, non-amplified metastatic breast Cancer","volume":"28","author":"Ma","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103235_bb0395","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting alterations in the RAF\u2013MEK pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103235_bb0400","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.24.00731","article-title":"Efficacy and safety of Taletrectinib in Chinese patients with ROS1+ non-small cell lung Cancer: the phase II TRUST-I study","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103235_bb0405","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.20.03025","article-title":"Updated integrated analysis of the efficacy and safety of Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung Cancer","volume":"39","author":"Dziadziuszko","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103235_bb0410","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103235_bb0415","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jtho.2025.05.023","article-title":"Updated efficacy and safety from the phase 2 PHAROS study of Encorafenib plus Binimetinib in patients with BRAF V600E-mutant metastatic NSCLC\u2014A brief report","volume":"20","author":"Riely","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103235_bb0420","doi-asserted-by":"crossref","first-page":"172","DOI":"10.21037\/tlcr.2016.04.07","article-title":"The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer","volume":"5","author":"Jakobsen","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103235_bb0425","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103235_bb0430","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Breast Cancer","author":"National Comprehensive Cancer Network","year":"2026"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:10:56Z","timestamp":1792714256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":86,"alternative-id":["S0305737226001490"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103235","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of maintaining the TKI backbone in oncogene-driven NSCLC after progression","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103235"}}